Quotidian Technical Highlights on Selected Healthcare Stocks -- GlaxoSmithKline, Synergy Pharma, Teva Pharma, and Perrigo

Thursday, April 5, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, April 05, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. 

Today we are offering reports on GSK, SGYP, TEVA, and PRGO which can be accessed for free by signing up to www.wallstequities.com/registration. This morning, WallStEquities.com covers the Healthcare sector, which is made up of companies that specialize
in products and services related to health and medical care. Four equities have been lined up for scanning, and they are: GlaxoSmithKline PLC (NYSE: GSK), Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), and Perrigo Co. PLC (NYSE: PRGO). All you have to do is sign up today for this free limited time offer by clicking the link below.



On Wednesday, shares in Brentford, the UK headquartered GlaxoSmithKline PLC recorded a trading volume of 3.89 million shares. The stock ended at $39.92, rising 1.63% from the last trading session. The Company's shares have gained 8.54% in the last month and 8.10% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 7.02% and 3.46%, respectively. Furthermore, shares of GlaxoSmithKline, which engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide, have a Relative Strength Index (RSI) of 68.97. 

On March 08th, 2018, GlaxoSmithKline and Innoviva, Inc. announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI), an inhaled corticosteroid/long-acting ?2-agonist combination, in patients whose asthma is already adequately controlled on both an inhaled corticosteroid and long-acting ?2-agonist.

On April 04th, 2018, research firm Exane BNP Paribas upgraded the Company's stock rating from 'Neutral' to 'Outperform'. Get the full research report on GSK for free by clicking below at:


Synergy Pharmaceuticals

New York headquartered Synergy Pharmaceuticals Inc.'s stock finished yesterday's session 1.65% higher at $1.85 with a total trading volume of 3.69 million shares. The stock is trading below their 50-day moving average by 9.45%. Shares of the Company, which focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders, have an RSI of 44.61. The free technical report on SGYP can be accessed at:


Teva Pharmaceutical Industries

At the close of trading on Wednesday, shares in Petach Tikva, Israel headquartered Teva Pharmaceutical Industries Ltd rose 1.71%, ending the day at $17.24. The stock recorded a trading volume of 6.20 million shares. The Company's shares are trading 10.31% below their 50-day moving average. Moreover, shares of Teva Pharma, which develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide, have an RSI of 39.68. 

On March 20th, 2018, research firm Jefferies resumed its 'Hold' rating on the Company's stock, with a target price of $19 per share.

On March 26th, 2018, Teva Pharma announced the launch of a generic version of Lialda® (mesalamine) delayed-release tablets, 1.2 g, in the US. Mesalamine delayed-release tablets are indicated for the induction of remission in adults with active, mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis. Sign up for free on Wall St. Equities and claim the latest report on TEVA at:



Dublin, Ireland headquartered Perrigo Co. PLC's shares ended the day 0.69% higher at $83.39 with a total trading volume of 742,867 shares. The stock has gained 0.70% in the last month and 24.82% over the past year. The Company's shares are trading 0.36% above their 200-day moving average. Additionally, shares of Perrigo, which manufactures and supplies over-the-counter healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide, have an RSI of 48.60. 

On March 07th, 2018, Perrigo announced that it has received final approval from the US FDA for the store brand OTC equivalent of Mucinex® DM Maximum Strength (Guaifenesin and Dextromethorphan Hydrobromide Extended-Release Tablets, 1200 mg/60 mg). This product will be packaged and marketed as a store brand or retailer 'own label' brand and will provide consumers with a high-quality, value alternative to Mucinex®DM Maximum Strength. See the free research coverage on PRGO at:



Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


CONTACTFor any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: info@wallstequities.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Cision View original content:http://www.prnewswire.com/news-releases/quotidian-technical-highlights-on-selected-healthcare-stocks----glaxosmithkline-synergy-pharma-teva-pharma-and-perrigo-300624906.html

SOURCE Wall St. Equities

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store